FrekaminTM I.V. is a tetracycline antibiotic currently approved by the US Food and Drug Administration for the treatment of minocycline-susceptible Acinetobacter species infections. Minocycline has significant in vitro activity both against S. aureus and coagulase-negative staphylococci, including community as well as nosocomial MRSA isolates. Minocycline has the potential to become an important part of the armamentarium against emerging infections such as MRSA and A. baumannii.
Supplied in glass vial packed in a mono carton along with pack insert.
| Adult patients | Patients with renal Impairment | Paediatric patients (aged above 8 years) |
|
Initial dose of 200 mg, then 100 mg every 12 hours, and should not exceed 400 mg in 24 hours. |
The total daily dosage should not exceed 200 mg in 24 hours in patients with renal impairment. Current data are insufficient to determine if a dosage adjustment is warranted. |
Initial dose of 4 mg/kg, then 2 mg/kg every 12 hours; should not exceed the usual adult dose.
|
FrekaminTM is indicated in the treatment of the following infections due to susceptible isolates of the bacteria:
Composition: Each vial contains Minocycline hydrochloride USP 100 mg
Dosage form: Injection (Lyophilized powder for solution).
